BioArctic

BioArctic FCF Growth

The Year-over-Year Free Cash Flow Growth of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 514.27 %. In the previous year, Year-over-Year Free Cash Flow Growth was -213.47 % — a change of -340.91% (higher).

FCF Growth

514.27 %

YoY

-340.91%

Last updated:

Year-over-Year Free Cash Flow Growth of BioArctic is 2025 514.27 % . Year-over-Year Free Cash Flow Growth of BioArctic was 2024 -213.47 % . It decreases by -340.91% higher compared to the previous year.

The BioArctic FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-47.22 SEK
Jan 1, 2019
258.53 SEK
Jan 1, 2020
-132.36 SEK
Jan 1, 2021
-38.19 SEK
Jan 1, 2022
69.36 SEK
Jan 1, 2023
780.99 SEK
Jan 1, 2024
-213.47 SEK
Jan 1, 2025
514.27 SEK
The BioArctic FCF Growth history
YEARFCF GrowthYoY
514.27 %-340.91%
-213.47 %-127.33%
780.99 %+1,026.04%
69.36 %-281.61%
-38.19 %-71.15%
-132.36 %-151.20%
258.53 %-647.46%
-47.22 %-60.86%
-120.65 %-103.27%
3,689.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Year-over-Year Free Cash Flow Growth of BioArctic is 514.27 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth BioArctic since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BioArctic

All Key Metrics — BioArctic